evipedia.aidev
← Back

Psilocybin for Health & Longevity

Evidence Review created on 08/21/2026 using AI4L / Grok 4

Also known as: 4-PO-DMT, Psilocybine, 4-phosphoryloxy-N,N-dimethyltryptamine, O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine

Motivation

Psilocybin is a naturally occurring compound found in certain mushrooms. The body quickly converts it into an active form that briefly activates serotonin receptors and changes how brain networks communicate. Interest among health- and longevity-oriented adults comes from two linked ideas: that a small number of closely supported high-dose sessions can produce lasting shifts in mood and habit, and that the same biology might touch aging processes well beyond psychiatry.

Ceremonial use of these mushrooms is centuries old. Laboratory chemistry and mid-century psychiatry then gave way to decades of prohibition, followed by a modern wave of controlled sessions for depression, end-of-life distress, and addiction. Cell and animal experiments have since been offered as a reason to consider the same compound in aging research.

This review examines the human evidence for those mental-health and habit effects, the animal and cell data behind the longevity hypothesis, how the compound is handled in the body, who is typically excluded from sessions, and the legal, sourcing, and monitoring realities of a highly restricted compound used as a short-course intervention rather than a daily longevity drug.

Benefits - Risks - Protocol - Conclusion

High-level overviews that name psilocybin directly, or discuss its therapeutic category, covering clinical use, mechanisms, or the longevity hypothesis.

Huberman maps chemistry, serotonin-receptor-driven neuroplasticity (the brain’s ability to rewire), depression and addiction trials, dose bands, session phases, and setting risks.

Attia dissects the 2025 Kato cell-and-mouse longevity paper, separating serotonin-receptor and telomere hypotheses from what animal data can say about human aging.

Patrick’s interview with Griffiths covers mystical-type experience, depression and cancer work, dose, and why preparation, setting, and psychiatric screening dominate risk.

Lifespan.io walks through Kato’s fibroblast lifespan extension and late-life mouse survival data, including sirtuin-1 (an enzyme that regulates cellular aging) and senescence (cells stopping division) findings, for a longevity audience.

Kresser and Gorman review psychedelic-assisted psychotherapy, the supported-session category that includes psilocybin, covering trial status, compound-specific uses, and clinician training.

Life Extension Magazine mentions the compound only inside broader depression and anxiety protocols, not as a standalone high-level review.

Grokipedia

Encyclopedic survey of chemistry, indigenous use, pharmacology, clinical research, adverse effects, and legal status for the compound itself.

Examine

Examine’s intervention page grades a small evidence base for cognition and mood and collects trial summaries for depression, anxiety, and related uses.

ConsumerLab

No ConsumerLab article on psilocybin was found. ConsumerLab does not typically cover Schedule I psychedelic compounds.

Systematic Reviews

PubMed systematic reviews and meta-analyses that quantify antidepressant effects, dose, cancer-related distress, or acute harms.

Seven trials (436 people) found a medium antidepressant effect (Hedges’ g = 0.66 (a standardized effect size)) and flagged expectancy.

Six randomized controlled trials (RCTs; 427 people) showed medium effects and about threefold higher response and remission versus comparators through six weeks.

Dose-response analysis placed the antidepressant ED95 (95% effective dose) near 25 mg/70 kg for primary depression; side effects also rose with dose.

Cochrane review: classical psychedelics may reduce anxiety and depression in life-threatening illness; certainty is low because blinding fails.

Six trials (n=528) found higher acute nausea, headache, anxiety, dizziness, and blood pressure, generally resolving within 48 hours.

Mechanism of Action

Psilocybin is a prodrug (inactive precursor) that intestinal and tissue alkaline phosphatase rapidly converts to psilocin, the molecule that crosses into the brain. Psilocin is a partial agonist at 5-HT2A (serotonin receptor subtype 2A), with additional activity at 5-HT2C and 5-HT1A (two further serotonin receptor subtypes) and weaker activity at 5-HT2B (a serotonin receptor linked to heart-valve injury when stimulated chronically). Occupancy of cortical 5-HT2A receptors disrupts the default mode network (the brain system active during self-focused rest), increases communication across normally segregated networks, and, in animals, rapidly grows dendritic spines (the receiving contacts on neurons). These changes are proposed to open a plasticity window lasting days.

Two accounts compete. One holds that a personally meaningful, often mystical-type experience mediates later benefit. The other holds that 5-HT2A-linked structural plasticity can occur even if the subjective storm is reduced. Both remain under test.

Psilocin’s plasma half-life is about 3 hours; oral subjective effects last roughly 4–6 hours, with peak plasma levels near 2 hours. Clearance is mainly via MAO-A (monoamine oxidase A, an enzyme that breaks down serotonin-like molecules) and glucuronidation (attaching a sugar molecule so the compound can be excreted) by UGT1A9 and UGT1A10 (gut and liver conjugation enzymes), not cytochrome P450 oxidation, so classic CYP drug–drug interactions are limited. 5-HT2A is also expressed on immune cells, fibroblasts, and heart tissue—the proposed basis for anti-inflammatory and cellular-aging hypotheses, and for theoretical heart-valve risk if 5-HT2B is stimulated often.

Historical Context & Evolution

Mesoamerican cultures used Psilocybe mushrooms in ceremonial healing long before European contact. In 1958 Albert Hofmann isolated psilocybin and described its effects after self-administration. 1950s–60s psychiatry tested it as an adjunct to psychotherapy. After cultural backlash, the U.S. Controlled Substances Act placed it in Schedule I (no accepted medical use, high abuse potential under that statute), which sharply cut clinical research rather than disproving earlier observations.

Work resumed in tightly controlled settings. A 2006 Johns Hopkins study in healthy volunteers showed that a high oral dose could occasion complete mystical-type experiences with lasting attributions of personal meaning (Griffiths et al., 2006). Randomized trials then reported large, sometimes months-long reductions in depression and anxiety among people with cancer (Griffiths et al., 2016; Ross et al., 2016), followed by waitlist and active-control trials in major depression. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designations for treatment-resistant and major depression; those designations accelerate review and do not equal approval. Oregon’s Measure 109 created licensed adult service centers; Australia authorized authorized psychiatrists to prescribe in 2023. A 2025 Emory/Baylor cell-and-mouse paper reporting delayed senescence and higher late-life survival in aged mice is what pulled the compound into longevity debates (Kato et al., 2025). That finding has not been replicated in humans.

Expected Benefits

High 🟩 🟩 🟩

Depressive symptom reduction ⚠️ Conflicted

Psilocybin with psychological support can reduce depressive symptoms after one or two high-dose sessions, including in cancer-related depression, likely via 5-HT2A agonism, network desynchronization, and a days-long plasticity window. Meta-analyses of randomized trials report medium effects versus comparators. Compass Pathways and the Usona Institute fund much of the large-trial evidence and have a direct financial interest in approval. A 2026 treatment-resistant trial missed its primary endpoint; a head-to-head versus a common daily antidepressant was not superior on its main scale; unblinding is common.

Magnitude: Hedges’ g = 0.66 (95% confidence interval [CI] 0.46 to 0.86) versus comparator in seven trials (436 people) (Metaxa & Clarke, 2024). A 25 mg dose lowered Montgomery-Åsberg Depression Rating Scale (MADRS, a clinician depression score; 0–60) by 12.3 points more than niacin at day 43 (Raison et al., 2023). In treatment-resistant depression, 25 mg beat 1 mg by 6.6 MADRS points at week 3 (Goodwin et al., 2022); the later EPISODE trial did not beat nicotinamide on binary response (17.0% vs 10.6%).

Medium 🟩 🟩

In people with life-threatening cancer, a single moderate-to-high dose plus psychotherapy has produced rapid drops in anxiety and existential distress, with many participants still improved at 6–6.5 months. Mystical-type intensity often tracks the change. Samples are small, crossover designs leak expectancy, and Cochrane judged certainty low.

Magnitude: About 80% of participants in a 51-person high-dose versus very-low-dose trial still had clinically significant drops in anxiety at 6 months (Griffiths et al., 2016). A 29-person niacin-controlled trial found 60–80% with enduring anxiety-reducing effects at 6.5 months (Ross et al., 2016). Cochrane pooled STAI-Trait (anxiety scale 20–80) mean difference −8.41 (95% CI −12.92 to −3.89) for classical psychedelics versus active placebo (Schipper et al., 2024).

Fewer heavy drinking days in alcohol use disorder

Two high-dose sessions embedded in 12 weeks of motivational and cognitive-behavioral psychotherapy reduced heavy drinking more than the same psychotherapy plus diphenhydramine (an antihistamine active placebo). The signal is a single multicenter randomized trial, not a meta-analysis.

Magnitude: Heavy-drinking days over 32 weeks were 9.7% with psilocybin versus 23.6% with diphenhydramine (mean difference 13.9 percentage points; 95% CI 3.0 to 24.7) in 93 treated adults (Bogenschutz et al., 2022).

Low 🟩

Cluster-headache attack frequency ⚠️ Conflicted

A patient-informed pulse of three low-moderate doses (0.143 mg/kg, about 5 days apart) missed its primary endpoint in a small first-round randomized trial, then cut attack frequency by about half in a blinded extension. Acute psychedelic intensity did not predict benefit.

Magnitude: First-round change was −3.2 versus +0.03 attacks/week (Cohen’s d = 0.69 (a standardized mean difference); p=0.251 (the chance of this difference if there were no real effect); 14 people) (Schindler et al., 2022). The extension fell from 18.4 to 9.8 attacks/week (p=0.013) (Schindler et al., 2024).

Smoking abstinence versus nicotine-patch care

In psychiatrically healthy smokers, one 30 mg/70 kg dose plus cognitive behavioral therapy (CBT, structured talk therapy for changing habits) produced higher biochemically verified 6-month abstinence than an 8–10 week nicotine patch plus the same CBT. The trial was unblinded; earlier open-label work had suggested large effects.

Magnitude: Prolonged 6-month abstinence was 40.5% (psilocybin) versus 10.0% (patch); odds ratio (OR, odds of the outcome vs the comparator) 6.12 (95% CI 1.99 to 23.26). Seven-day point-prevalence abstinence was 52.4% versus 25.0% (Johnson et al., 2026).

Obsessive-compulsive symptom reduction

Repeated high-dose sessions reduced obsessive-compulsive symptoms in a small Phase 1 randomized trial, likely via 5-HT2A agonism. The sample was 15 people; benefit lessened by six months.

Magnitude: After eight weeks (at least four high doses), 73.3% met response on the Yale-Brown Obsessive Compulsive Scale (YBOCS, an obsessive-compulsive disorder [OCD] severity score; ≥35% drop) and 40% were in remission (15 people) (Moreno et al., 2026).

Parkinson’s mood, cognition, and motor symptoms

In people with mild-to-moderate Parkinson’s disease, two supported doses (10 then 25 mg) improved mood, some cognitive tests, and motor scores for weeks. 5-HT2A-linked plasticity is the proposed mechanism. Evidence is a 12-person open-label safety study, not a randomized trial.

Magnitude: MADRS fell 9.3 points at 3 months (Hedges’ g = 1.0) in 12 people; clinician motor scores on the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS Part III, a Parkinson’s motor exam) fell 4.6 points at 1 month (Bradley et al., 2025).

Eating-disorder symptom reduction in anorexia nervosa

In adult women with anorexia nervosa, one to three supported doses reduced eating-disorder interview scores in small open-label pilots, likely via 5-HT2A-linked flexibility. Samples are 10–21 people; one later suicide attempt occurred in follow-up. Not a randomized trial.

Magnitude: Eating Disorder Examination (EDE, an anorexia-severity interview) scores improved (Cohen’s d = 0.98) at 6 months in 21 women after three doses (Douglass et al., 2026). An earlier 10-person single-dose study was a safety and feasibility trial (Peck et al., 2023).

Lasting well-being and personality openness in healthy adults

In screened healthy adults, a supported high-dose session can occasion a mystical-type experience later ranked among life’s most meaningful events and linked to higher well-being, likely via 5-HT2A-driven network change. A pooled analysis found lasting increases in Openness (curiosity and aesthetic interest). Volunteers were spiritually pre-selected.

Magnitude: At 14 months, 58% rated the session among their five most personally meaningful life events and 64% reported increased well-being or life satisfaction (Griffiths et al., 2008). Openness rose after high-dose sessions and persisted over a year when a complete mystical-type experience occurred (MacLean et al., 2011).

Speculative 🟨

Cellular and late-life organismal lifespan

Psilocin extended cultured-cell lifespan 29–57% and preserved telomeres; mouse dosing raised 10-month survival from 50% to 80%. No human aging trial exists. Mechanistic and preclinical only (Kato et al., 2025).

Systemic anti-inflammatory effects

5-HT2A activation reduces inflammatory signaling in several animal models. Human longevity-relevant inflammation outcomes after psilocybin have not been shown in controlled trials. The basis is mechanistic and preclinical only (Flanagan & Nichols, 2018).

Benefit-Modifying Factors

  • Prior psychedelic exposure: Metaregression (testing whether study features change the pooled effect) in the depression meta-analysis associated previous psychedelic use with larger symptom drops, which may mark expectancy as much as biology (Metaxa & Clarke, 2024).
  • Baseline symptom load: Higher starting depression scores leave more room to fall. No established blood-test predictor of response exists; blood pressure is a safety gate, not a benefit biomarker.
  • Depression type and severity: Secondary (cancer-related) depression showed a larger pooled effect than primary depression; treatment-resistant samples are less consistent (Goodwin et al., 2022 positive; EPISODE trial inconclusive).
  • Mystical-type intensity: Higher ratings of unity, sacredness, and insight have predicted later mood and well-being in cancer and depression cohorts, though not every 12-month depression change (Gukasyan et al., 2022).
  • Psychological support quality: Alliance and preparation track outcomes in assisted-therapy trials; isolated unsupervised use is a different intervention.
  • Age: Older adults in depression meta-regression improved more; Kato’s mouse work started at a late-life equivalent. Cardiovascular screening becomes more important with age.
  • Sex: Human efficacy trials are mixed and not powered for sex interaction. Some rodent work shows sex-specific stress-axis recruitment; Kato used females only.
  • Genetic variation: HTR2A (the gene encoding the 5-HT2A receptor) variants are biologically plausible modifiers of intensity; they are not used as clinical dose keys. Psilocin is not a major CYP2D6 (a common drug-metabolizing enzyme) substrate.
  • Concomitant daily antidepressants: Ongoing selective serotonin reuptake inhibitors (SSRIs, common daily antidepressants) can blunt the acute psychedelic effect; a small open-label Compass study still saw MADRS improvement on an SSRI (Goodwin et al., 2023).
  • Microdosing context: Repeated sub-hallucinogenic doses have not shown consistent mood or cognition benefits beyond placebo in healthy adults (Meshkat et al., 2026; Szigeti et al., 2021).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Acute nausea, headache, and dizziness

These are the most reproducible somatic effects of therapeutic oral doses, consistent with gut and vascular 5-HT receptor stimulation. They are usually confined to the session day and the following 24–48 hours in trial settings.

Magnitude: Versus comparators, nausea relative risk (RR, risk in the psilocybin arm divided by comparator risk) 8.85 (95% CI 5.68 to 13.79), headache RR 1.99 (1.06 to 3.74), dizziness RR 5.81 (1.02 to 33.03) across six trials (528 people) (Yerubandi et al., 2024). Menon pooled headache RR 1.78 and dizziness RR 6.52 (Menon et al., 2025).

Transient blood-pressure and heart-rate rise

Oral psilocybin reliably raises blood pressure and heart rate during the acute window, a sympathomimetic (fight-or-flight-like) effect that matters in coronary disease, uncontrolled hypertension, or aneurysm (a ballooning weak spot in an artery wall) risk. Trial participants are pre-screened; unsupervised users are not.

Magnitude: Elevated blood pressure RR 2.29 (95% CI 1.15 to 4.53) in the therapeutic-dose meta-analysis (Yerubandi et al., 2024). The U.S. National Institute on Drug Abuse lists increased heart rate and blood pressure as standard physical effects.

Challenging psychological experience

Anxiety, fear, paranoia, and a sense of ego dissolution (losing the usual feeling of a separate self) that the person cannot handle are common at high dose, even in screened rooms. In surveys of unsupervised mushroom use, a substantial minority rate the episode among the worst of their lives. In trials, anxiety is increased but paranoia and thought disorder were not significantly raised in Yerubandi’s pool.

Magnitude: Anxiety RR 2.27 (95% CI 1.11 to 4.64) in therapeutic-dose trials (Yerubandi et al., 2024). In 1,993 unsupervised “worst session” reports, 39% rated it among their five hardest lifetime events and 11% put themselves or others at risk of physical harm (Carbonaro et al., 2016). In trials, paranoia and transient thought disorder were not significantly increased.

Medium 🟥 🟥

Suicidal ideation or self-injury in depressed samples

Serious psychiatric adverse events cluster in people who already have depression, not in healthy-volunteer studies. Compass’s phase 2 treatment-resistant trial recorded suicidal ideation, behavior, or self-injury in every dose arm (Goodwin et al., 2022). EPISODE reported more suicidal ideation on 25 mg dosing days.

Magnitude: Hinkle estimated serious adverse events in about 4% of participants with preexisting neuropsychiatric disorders and none in healthy participants across classic psychedelic studies (Hinkle et al., 2024). EPISODE: suicidal ideation on dosing days 4% (25 mg) versus 1–2% in comparators (Mertens et al., 2026).

Mania or psychosis in vulnerable people

Psilocybin can unmask mania or a psychotic process in those with bipolar I disorder, schizophrenia, or a first-degree family history of those conditions. Contemporary trials exclude these groups, so trial “safety” does not describe them. Unsupervised surveys include cases of enduring psychiatric worsening.

Magnitude: Hinkle found no persistent psychotic disorders in contemporary supervised high-dose research cohorts, while noting heterogeneous adverse-event capture (Hinkle et al., 2024). Carbonaro reported a small number of survey cases that appeared associated with lasting psychotic symptoms (Carbonaro et al., 2016).

Low 🟥

Hallucinogen persisting perception disorder (HPPD)

HPPD is re-experiencing geometric visuals or other perceptual remnants long after the drug has cleared. It is rare in modern trials; EPISODE recorded one serious case after 25 mg. Unsupervised literature describes occasional flashbacks that are not always distressing.

Magnitude: One serious HPPD reaction in the 144-person EPISODE trial (Mertens et al., 2026). Hinkle found no HPPD reports in the contemporary supervised set available through early 2024 (Hinkle et al., 2024).

Speculative 🟨

Heart-valve disease with frequent 5-HT2B stimulation

Chronic 5-HT2B stimulation caused fenfluramine-type valve injury. Psilocin has that activity. Intermittent sessions differ from daily microdosing. No human valve series exists; the concern is mechanistic only (McIntyre, 2023).

Risk-Modifying Factors

  • Personal or family psychosis/bipolar history: The strongest psychiatric risk modifier; these groups are excluded from almost every modern trial (Johnson et al., 2008).
  • Set and setting: Unsupervised, chaotic, or high-dose mushroom use drives Carbonaro’s harm reports; two-therapist rooms, eyeshades, and a defined integration plan are the trial counterweight.
  • Cardiovascular baseline: Uncontrolled hypertension, recent infarction (heart attack), or clinically important arrhythmia amplify the acute pressor (blood-pressure-raising) effect.
  • Age: Older adults may gain psychiatric benefit but have less vascular reserve; Kato’s mice were late-life females, not a cardiac-safety dataset.
  • Sex: Acute subjective intensity is sometimes reported as higher in women; suicide-related events in treatment-resistant depression (TRD) trials have not been cleanly sex-stratified.
  • Lithium: Online experience reports link classic psychedelics plus lithium to seizures, unlike lamotrigine (Nayak et al., 2021).
  • Dose and frequency: Perez linked higher milligram amounts to more physical discomfort, blood-pressure rise, nausea, and headache (Perez et al., 2023). Daily or near-daily use is the valvular hypothetical, not the 1–2 session model.
  • HTR2A and metabolic genes: Receptor variants may change intensity; UGT and MAO-A activity could change exposure. Neither is a validated dosing test.

Key Interactions & Contraindications

  • Lithium (mood stabilizer): Absolute contraindication in practice. Online reports associate co-use with seizures (Nayak et al., 2021). No safe timing interval is established.
  • MAO inhibitors (phenelzine, tranylcypromine, moclobemide, some Banisteriopsis preparations): Caution. MAO-A clears psilocin; inhibition can raise exposure and serotonergic load. Protocols typically require washout.
  • Daily SSRIs/SNRIs (sertraline, escitalopram, venlafaxine; SNRIs are serotonin-norepinephrine reuptake inhibitors): Caution. They often blunt the acute psychedelic effect; abrupt stop has its own withdrawal. A small open-label Compass study still saw antidepressant change on an SSRI (Goodwin et al., 2023).
  • 5-HT2A antagonists (ketanserin, risperidone, olanzapine): Caution. They abort or prevent the psychedelic effect; sometimes used as rescue, they also erase the intended session.
  • Tramadol, bupropion, theophylline, and other seizure-threshold drugs: Caution with high-dose sessions; additive neurologic risk, especially if lithium is also in the picture.
  • Stimulants (amphetamine, high-dose caffeine, cocaine): Additive heart-rate and blood-pressure rise during the acute window; monitor or avoid same-day use.
  • Cannabis and alcohol: Caution. Can increase acute anxiety or confusion during the session; alcohol also undermines the addiction-related use case.
  • St John’s wort, 5-HTP (5-hydroxytryptophan, a serotonin precursor), SAMe (S-adenosylmethionine): Caution. Additive serotonergic tone; theoretical serotonin-excess risk, mainly with MAOIs present.
  • Other psychedelics (LSD [lysergic acid diethylamide], DMT [N,N-dimethyltryptamine], mescaline, MDMA [3,4-methylenedioxymethamphetamine]): Caution. Overlapping 5-HT2A/2B and cardiovascular load; combining them is not a studied therapeutic protocol.
  • Antihypertensives (lisinopril, amlodipine, hydrochlorothiazide): Not a metabolic interaction; blood pressure still rises acutely and then falls. Monitor rather than assume cancellation.

Populations who should avoid Psilocybin:

  • Personal history of schizophrenia, schizoaffective disorder (psychosis with mood episodes), or other primary psychotic disorder
  • Bipolar I disorder, or a first-degree relative with bipolar I or schizophrenia
  • Current manic episode or mixed state (mania and depression at once)
  • Uncontrolled hypertension, recent myocardial infarction (<90 days), decompensated heart failure (heart failure with fluid backup and poor organ perfusion), or known aneurysm
  • Pregnancy or breastfeeding (no reproductive-safety database)
  • Active lithium therapy
  • Age under 18 in medical protocols (almost no pediatric randomized-trial evidence)
  • Acute suicidality with plan or intent outside a high-monitoring research ward

Risk Mitigation Strategies

  • Psychiatric pre-screen: Structured interview for psychosis, bipolar I, and first-degree family history before any high-dose session, matching Johns Hopkins exclusion logic (Johnson et al., 2008).
  • Two-person support and defined setting: Continuous sober support in a quiet room for the 4–6 hour acute window reduces Carbonaro-type behavioral harm.
  • Cardiovascular check: Resting blood pressure and heart rate before dosing; postpone if pressure is in the hypertensive crisis range (severe, emergency-level high blood pressure) or symptoms of ischemia (inadequate blood flow to the heart) are present.
  • Dose selection: Therapeutic literature clusters at 20–30 mg/70 kg or a 25 mg fixed capsule; side-effect curves rise with milligrams (Perez et al., 2023).
  • SSRI handling: Planned washout under psychiatric follow-up, or an on-SSRI session with tempered expectancy (small Compass adjunct study), to avoid withdrawal harm or a blunted psychedelic effect.
  • Lithium hard stop: No co-administration; seizure reports make this a binary gate, not a monitor-and-see rule.
  • Rescue medications: Protocols stock a benzodiazepine for overwhelming anxiety and an antipsychotic 5-HT2A blocker for severe agitation, used sparingly so the session is not erased without cause.
  • Integration window: Scheduled follow-up in the days and weeks after, when the plasticity window is open and mood can swing in either direction, including suicidality in TRD.
  • Chronic-use valve caution: People microdosing for months are the 5-HT2B exposure group; intermittent 1–2 session medical use is a different risk shape (McIntyre, 2023).

Therapeutic Protocol

  • Johns Hopkins high-dose model: Two oral sessions (about 20 then 30 mg/70 kg) several weeks apart, with ~11 hours of preparatory and integrative psychotherapy (Davis et al., 2021). Roland Griffiths’s group popularized this depression protocol.
  • Compass/Usona single-capsule model: One 25 mg synthetic dose (COMP360 or Usona material) plus psychological support, as in Goodwin and Raison. Compass Pathways funds COMP360 and has a direct approval interest.
  • Imperial College two-dose versus SSRI model: Two 25 mg doses three weeks apart plus support, compared with daily escitalopram (Carhart-Harris et al., 2021). Not superior on the primary self-report scale.
  • Oregon licensed-service model: State-licensed facilitators run mushroom-based sessions legally for adults, without FDA drug approval. Facilitators are paid per service; that is a revenue interest in continued access.
  • Cluster-headache pulse: Three 0.143 mg/kg doses about 5 days apart (Schindler et al., 2022). Distinct from depression dosing and still exploratory.
  • Microdosing (Fadiman-style 1 day on, 2 off; Stamets-style stack): About 1–3 mg or 0.1–0.3 g dried mushroom. RCTs in healthy adults do not show reliable benefit beyond placebo.
  • Time of day: Morning or early afternoon. The 4–6 hour acute course plus afterglow would otherwise collide with sleep.
  • Half-life and schedule: Psilocin half-life ~3 hours (Brown et al., 2017). One session is a single oral dose, not split tablets across the day.
  • Genetics: No validated HTR2A or UGT dosing algorithm. Phenotype (prior sensitivity, SSRI occupancy) guides more than a gene panel.
  • Sex: No separate milligram chart. Body-weight dosing (mg/70 kg) is used in Hopkins protocols; Compass used a fixed 25 mg.
  • Age: Adults 21–65 dominate randomized trials. Older candidates need tighter blood-pressure and medication review; Kato’s mice started at a ~60–65-year human equivalent.
  • Baseline biology: Uncontrolled hypertension, drugs that affect heart rhythm, and pregnancy tests are gates. Depression severity shapes expected psychiatric effect more than a longevity blood test does.
  • Pre-existing conditions: Cancer-related distress is a studied indication; active psychosis, bipolar I, and lithium-treated bipolar illness are not.

Discontinuation & Cycling

  • Course length: This is a short-course intervention (one to three sessions), not a lifelong daily drug. Some people repeat months or years later if depression or drinking returns.
  • Withdrawal: No SSRI-like discontinuation syndrome is described after a single psilocybin session. Residual headache, fatigue, or mood lability can last 1–2 days.
  • Taper: Not applicable to the 25 mg session model. Taper applies to the daily antidepressants being stopped beforehand, not to psilocybin itself.
  • Cycling: Microdosing communities cycle (1 on / 2 off, or 4 days on / 3 off) on the theory of avoiding tolerance. That practice is not evidence-based for efficacy. High-dose therapy is spaced by weeks, then stopped.
  • Integration after stopping: Benefit in depression trials has lasted 3–12 months in some cohorts without redosing (Gukasyan et al., 2022); loss of effect is managed by another prepared session, not by escalation to daily use.

Sourcing and Quality

  • Synthetic pharmaceutical capsules: Usona Institute and Compass Pathways (COMP360) supply characterized 25 mg material made under good manufacturing practice. That is the form with published pharmacokinetic tables in healthy adults (Brown et al., 2017).
  • Licensed mushroom services: Oregon (and some Colorado) service centers dispense Psilocybe fruiting bodies under state rules. Potency still varies by species, flush, and dryness; licensed testing is the quality lever, not a brand name.
  • Unregulated dried mushrooms or gummies: Alkaloid content can range from negligible to several milligrams per gram. Misidentified Amanita and other toxic fungi, plus unlabeled tryptamines, are the practical contaminants.
  • Third-party potency testing: Where laboratories are legal, HPLC (high-performance liquid chromatography) assays of psilocybin and psilocin, plus heavy-metal and microbial screens, are what distinguish a known milligram dose from a guess.
  • Legal status as a quality filter: In the U.S. the compound remains Schedule I federally. Gray-market products marketed for longevity are not equivalent to trial capsules. Australia’s authorized-psychiatrist pathway and Oregon’s service centers are the two lawful adult channels most discussed.

Practical Considerations

  • Time to effect: Acute sensory and emotional effects begin at 20–40 minutes, peak near 2 hours, and fade by 4–6 hours. Psychiatric change, when it occurs, is often measurable the next day and may persist weeks to months.
  • Common pitfalls: Treating mushroom weight as a milligram dose; combining with lithium or MAOIs; skipping cardiovascular screening; redosing mid-session; treating microdosing as a proven geroprotective (cell-aging-protective) regimen after Kato.
  • Regulatory status: Not FDA-approved. Schedule I federally in the U.S. Oregon licensed services and Colorado regulated access exist beside that federal rule. Australia permits authorized psychiatrists to prescribe. Off-label “longevity” use has no approved indication.
  • Cost and access: Facilitated medical or Oregon-style sessions typically cost thousands of dollars per day including two staff, a private room, and integration visits. Insurers generally do not pay; cheaper daily antidepressants have a structural payer advantage that can shape guidelines and research funding.
  • Expectancy and blinding: People usually know they received a psychedelic. That inflates apparent benefit in unblinded or poorly blinded trials (Orsini et al., 2026) and is part of the evidence, not a footnote.

Interaction with Foundational Habits

  • Sleep: Direct, acute disruption. The 4–6 hour session and sympathetic activation delay sleep if dosing is late. Indirectly, depression improvement can later consolidate sleep. Practical point: morning sessions; no driving the same day.
  • Nutrition: Direct, modest. Fasting or a light low-fat meal is used to limit nausea. MAO-A metabolizes psilocin, but tyramine rules are far less critical than with irreversible MAOIs. Alcohol the same day increases confusion and undercuts the alcohol-use indication.
  • Exercise: None during the session (falls, traffic, overheating). Indirect/potentiating afterward: animal work shows psychedelics reopen a social-reward learning critical period (Nardou et al., 2023), so skill practice and training in the following days are the plausible pairing, not a gym session on the drug.
  • Stress management: Direct and bidirectional. The session is itself a controlled stressor (cortisol and heart rate rise). Preparation, breath work, and a trusted sitter lower the odds of a panic spiral. Lasting benefit, when present, often includes lower rumination rather than a blunted cortisol lab.

Monitoring Protocol & Defining Success

Before a first high-dose session, protocols document psychiatric history, a pregnancy test when applicable, resting blood pressure and heart rate, and current serotonergic or lithium use. There is no established longevity laboratory signature for psilocybin; inflammatory markers, if drawn, are interpreted as change from that person’s own baseline rather than as a drug target. During the session, blood pressure and mental state are checked repeatedly through the peak (about 1.5–3 hours) and until the person is clear to leave. Afterward, mood, sleep, substance use, and suicidality are re-checked at about 1 day, 1 week, 4 weeks, and 3 months—the window in which both benefit and delayed psychiatric worsening have been described. People who microdose for months are in a different monitoring category because of cumulative 5-HT2B exposure; echocardiography is a mechanistic precaution there, not a trial standard for two medical sessions.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting blood pressure <120/80 mmHg Acute pressor effect Conventional office goal is often <140/90 mmHg; postpone dosing in hypertensive crisis. Recheck during peak.
Resting heart rate 60–80 bpm Acute tachycardia Conventional resting range is often 60–100 bpm; higher resting rates plus stimulants compound session load.
Urine or serum hCG Negative Pregnancy exclusion hCG is human chorionic gonadotropin, the pregnancy hormone. No reproductive-safety database; test within 72 hours before dosing when pregnancy is possible.
hs-CRP No psilocybin-specific target; track change from personal baseline (functional goals often <0.7 mg/L) Speculative inflammation/longevity pathway hs-CRP is high-sensitivity C-reactive protein, a blood marker of systemic inflammation. Conventional cardiovascular cut-points use <1, 1–3, and >3 mg/L. Not required for psychiatric protocols.
PHQ-9 <5 (minimal symptoms) Primary psychiatric endpoint in non-trial use PHQ-9 is a nine-item self-report depression score. Conventional screening threshold is ≥10. Repeat at 1 week, 4 weeks, then 3–6 months.
  • Sleep continuity and next-day grogginess
  • Alcohol or cigarette use (timeline follow-back)
  • Cognitive flexibility and rumination, not just mood
  • Meaning-making versus lingering fear after the session
  • Emergence of mania, unusual beliefs, or suicidal thinking

Emerging Research

  • Phase 3 treatment-resistant depression (COMP360): NCT05711940 is a Compass-funded trial of two COMP360 administrations (n=572, active, not recruiting). A positive or negative primary MADRS result would move the conflicted TRD evidence more than another small academic RCT. Compass has a direct financial interest in approval.
  • Phase 3 major depression (Usona): NCT06308653 tests synthetic psilocybin in major depressive disorder (MDD; n=238, active, not recruiting). Usona funded the 2023 Raison RCT and has an institutional interest in this indication.
  • Advanced cancer distress: NCT05398484 is a recruiting phase 2/3 trial (n=200) on anxiety in advanced cancer, extending Griffiths/Ross rather than longevity biology.
  • Alzheimer neuroplasticity: NCT07721467 (not yet recruiting, n=200) asks whether psilocybin plus cognitive training changes a neuroplasticity composite—an aging-brain question, not a lifespan trial.
  • EPISODE already weakens the treatment-resistant case: The 2026 German randomized trial missed its primary response endpoint and recorded an HPPD case (Mertens et al., 2026). Phase 3 will show whether Goodwin 2022 generalizes.
  • Blinding as a threat to the whole literature: Orsini et al., 2026 quantify functional unblinding in psychedelic RCTs; high unblinding would shrink apparent effects toward expectancy.
  • Human aging gap: Kato’s 80% versus 50% late-life mouse survival (Kato et al., 2025) has no registered human lifespan or epigenetic-clock trial. A commentary on human longevity (Lerer, 2026) remains opinion, not data.
  • Chronic 5-HT2B risk: Valve surveillance in frequent microdosers would be the study that could weaken casual longevity combination use (McIntyre, 2023).

Conclusion

Psilocybin is a short-acting compound that activates serotonin receptors and is used as one or two supported sessions, not as a daily longevity supplement. In screened adults, those sessions can produce lasting improvements in depression, cancer-related distress, drinking, and smoking; healthy volunteers often report lasting well-being. The literature is mixed on depression that did not respond to usual care: one large company-funded study was positive on its main depression score, a later independent trial was not, and a comparison with a standard daily antidepressant was not clearly better. People usually know they received a psychedelic, so expectation shapes the measured effect.

The longevity claim rests on cells and aged mice—longer life of cells grown in the laboratory and better late-life survival—plus the idea that less depression, alcohol, and tobacco support a longer life. No human aging trial exists.

Main harms are predictable: nausea, headache, a temporary rise in blood pressure and heart rate, and psychologically overwhelming sessions. In people who already have depression, suicidal thinking can appear around dosing days. People with psychotic illness and those taking lithium are outside the safety data. Frequent use raises a theoretical heart-valve concern that occasional medical sessions do not test.

Much of the large-trial evidence is funded by Compass Pathways and the Usona Institute, which need regulatory approval. Session-based care is expensive; daily generic antidepressants are not. For a risk-aware adult optimizing long-term health, the evidence supports a narrow, prepared psychiatric and addiction role and does not support routine longevity use.

Top - Benefits - Risks - Protocol